Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock?
Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
Morgan Stanley Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $120
S&P 500 Futures Decline In Premarket Trading; GXO Logistics, Celsius Holdings Lead
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105
Blueprint Medicines Insider Sold Shares Worth $324,500, According to a Recent SEC Filing